French National Network of Clinical Research in Infectious Diseases Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2016
NCT02681263
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

French National Network of Clinical Research in Infectious Diseases (RENARCI)

Active Ingredients

Drugs in Phase 4 Trials (1)

temocillin (1 trial)

Drugs in Phase 3 Trials (1)

dalbavancin (dalvance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 4)

Infections (Phase 4)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2